Key Developments: Chugai Pharmaceutical Co Ltd (4519.T)
19 Jun 2013
Latest Key Developments (Source: Significant Developments)
Chugai Pharmaceutical Co., Ltd. Initiates Clinical Trials for Multiple In-Licensed Compounds in Cooperation with Roche Holding Ltd
Chugai Pharmaceutical Co., Ltd. announced that it has entered into license agreements with Roche Holding Ltd covering humanized anti-Met antibody MetMAb, for non-small cell lung cancer (NSCLC) and humanized anti-interleukin(IL)-13 antibody lebrikizumab for bronchial asthma which are both currently developed by Roche utilizing the Personalized Healthcare (PHC) approach and have also entered phase I clinical studies in the Japanese population. Under the agreement, Chugai obtains rights for the development and marketing of these compounds in Japan, and will make milestone payments to Roche. Full Article
Chugai Pharmaceutical Co., Ltd. announced that it has lowered its consolidated full-year outlook for revenue from JPY 403,000 million to JPY 395,200 million, operating profit from JPY 75,000 million to JPY 72,000 million and ordinary profit from JPY 75,500 million to JPY 73,100 million, but maintained the outlook for net profit of JPY 37,000 million and earning per share of JPY 67.99, for the fiscal year ending December 2011. The Company lowered the outlook due to the decreased sales, the impact of the earthquake, as well as the increased tax cost, among others. According to I/B/E/S Estimates, analysts were expecting the Company to report full-year revenue of JPY 401.77 billion and earning per share of JPY 71.59. Full Article
May 18 - Sony Corp plans to appoint Chugai Pharmaceutical Co Chief Executive Osamu Nagayama as chairman, the Nikkei reported.